RIPE-KG · Version 1.1.0 · Resource

ripekg:publication-details/RIPEAA805A88D874EA69C

https://w3id.org/ripe/ripe-kg/publication-details/RIPEAA805A88D874EA69C

Subject	Predicate	Object
`ripekg:evaluation/RIPEAA805A88D874EA69C`	`prov:used`	`ripekg:publication-details/RIPEAA805A88D874EA69C`The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties
`ripekg:publication-details/RIPEAA805A88D874EA69C`The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties	`prism:eIssn`	2107-0180
`ripekg:publication-details/RIPEAA805A88D874EA69C`The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties	`prism:endingPage`	147
`ripekg:publication-details/RIPEAA805A88D874EA69C`The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties	`prism:issn`	0378-7966
`ripekg:publication-details/RIPEAA805A88D874EA69C`The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties	`prism:publicationDate`	2014-12-05
`ripekg:publication-details/RIPEAA805A88D874EA69C`The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties	`prism:publicationName`	European Journal of Drug Metabolism and Pharmacokinetics
`ripekg:publication-details/RIPEAA805A88D874EA69C`The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties	`prism:startingPage`	139
`ripekg:publication-details/RIPEAA805A88D874EA69C`The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties	`dcterms:publisher`	`ripekg:publisher/RIPEP13F074DA04C2917A`Springer Science and Business Media LLC
`ripekg:publication-details/RIPEAA805A88D874EA69C`The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties	`dcterms:title`	The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties
`ripekg:publication-details/RIPEAA805A88D874EA69C`The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties	`rdf:type`	`http://purl.org/spar/fabio/BibliographicMetadata`
`ripekg:publication-details/RIPEAA805A88D874EA69C`The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties	`rdf:type`	`rdfs:Resource`
`ripekg:publication-details/RIPEAA805A88D874EA69C`The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties	`rdf:type`	`owl:Thing`
`ripekg:publication-details/RIPEAA805A88D874EA69C`The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties	`rdf:type`	`ripe:IntegrityAssessmentEvidence`Integrity assessment evidence
`ripekg:publication-details/RIPEAA805A88D874EA69C`The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties	`rdf:type`	`ripe:PublicationDetails`Publication details
`ripekg:publication-details/RIPEAA805A88D874EA69C`The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties	`rdf:type`	`tido:Evidence`
`ripekg:publication-details/RIPEAA805A88D874EA69C`The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties	`prov:wasGeneratedBy`	`ripekg:evidence-aggregation/RIPEAA805A88D874EA69C`
`ripekg:publication-details/RIPEAA805A88D874EA69C`The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties	`prov:wasMemberOf`	`ripekg:research-integrity-assessment/RIPEAA805A88D874EA69C`
`ripekg:publication-details/RIPEAA805A88D874EA69C`The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties	`ripe:concerns`	`ripekg:work/10.1007%2Fs13318-014-0242-5`The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties
`ripekg:publication-details/RIPEAA805A88D874EA69C`The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties	`tido:supports`	`ripekg:integrity-assessment-hypothesis/RIPEAA805A88D874EA69C-human-1-1`
`ripekg:publication-details/RIPEAA805A88D874EA69C`The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties	`tido:supports`	`ripekg:integrity-assessment-hypothesis/RIPEAA805A88D874EA69C-inspectai-1-1`